However, mTOR inhibitors may have both pro- and anti-inflammatory actions and prompt both initial stimulation of Type 1 T helper (Th1) CD4+ T cells as well as long-term expansion of Tregs in cancer [29,30]. The gene discussed is CD4; the disease is cancer.